SBIR-STTR Award

Muscle Preservation During Weight Loss in Older, Overweight Individuals
Award last edited on: 8/25/2016

Sponsored Program
SBIR
Awarding Agency
NIH : NIA
Total Award Amount
$146,667
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Robert R Wolfe

Company Information

Essential Blends LLC

1930 Lynx Lane
Fairbanks, AK 99709
   (281) 910-1648
   N/A
   essentialblends.co/
Location: Single
Congr. District: 00
County: Fairbanks North Star Borough

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2015
Phase I Amount
$146,667
The overall goal of this project is to test a meal replacement beverage that will ultimately preserve muscle loss during calorie restriction weight loss (CRWL) in obese older individuals. We previously developed a meal replacement rich with a proprietary blend of essential amino acids (TMR) that was more than three times as effective as whey protein in stimulating muscle protein synthesis (MPS) in the elderly. Utilizing this TMR and protein intake based on minimal protein requirements (0.8 gm protein/kg/day), we demonstrated a greater reduction in adipose tissue compared to a competitive meal replacement. Even so, volunteers still lost some muscle mass using the TMR. This likely reflected the fact that the optimal protein intake in older individuals is significantly greater thn 0.8 g/kg/day, and the hypocaloric condition of CRWL further elevated the need for optimal protein. In our formulation (MyoEon), we have now increased the absolute amount of EAAs and also included citrulline to even further promote the availability of EAAs to skeletal muscle. Although MyoEon is sufficiently developed for testing the central hypothesis of this project, part of this Phase 1 project will be to further optimize several aspects of product. The overarching hypothesis of this proposal is that the ingestion of MyoEon will foster an improvement in net protein synthesis, through an increased rate of protein synthesis and a decreased rate of protein breakdown as compared to a commercially available "high protein" meal replacement (Bariatric Advantage). Specific Aim 1: We will optimize the palatability and cost for ingredients, production, packaging, and fulfillment, which will validate the hypothesis that MyoEon can be profitably sold in retail markets. We will work directly with our food science partner (Mattson, Inc., Foster City, CA; http://www.foodcom.com/) to establish the criteria of acceptance for the formulation of MyoEon. The metric of success will be defined by establishing the feasibility of MyoEon as a palatable (determined by focus groups) and cost effective (total costs per product less than $1.00) product for use in weight loss. Specific Aim 2: We will demonstrate the feasibility of MyoEon to preserve lean body mass during CRWL as compared to Bariatric Advantage, through increased net protein synthesis, calculated as the difference between protein synthesis and breakdown determined by stable isotope tracer methodology. Demonstration that MyoEon is superior to the highest quality competitor will represent the metric of success for this aim and serve as the mechanistic underpinning for a Phase II randomized, clinical trial (RCT) performed in conjunction with the Mountain West Clinical Translational Research - Infrastructure Network. In this RCT, we will establish the effectiveness of MyoEon vs Bariatric Advantage in an outcome study focused on maintenance of muscle mass and improvement of functional capacity, as well as amplification of the metabolic benefits of weight loss.

Public Health Relevance Statement:


Public Health Relevance:
This study is designed to evaluate the impact of high-density essential amino acids + citrulline meal replacement (MyoEon) on the promotion of increased muscle protein synthesis relative to muscle protein breakdown as compared to Bariatric Advantage. These data will then be utilized to derive the variability of the response to the meal replacement, and will facilitate the accurate calculation of statistical power for multi-site randomized clinical trial.

NIH Spending Category:
Aging; Clinical Research; Clinical Trials and Supportive Activities; Nutrition; Obesity; Prevention

Project Terms:
3 year old; Acceleration; Activities of Daily Living; Address; Adipose tissue; Age-Years; Aging; Arginine; Bariatrics; base; Beverages; Biological Preservation; Blood flow; Body mass index; Body Weight; Body Weight decreased; Caloric Restriction; Cities; Citrulline; Clinical; cost; cost effective; Data; density; Deposition; design; Development; Diet; Drug Formulations; Effectiveness; Elderly; Energy Intake; Essential Amino Acids; Focus Groups; food science; Fostering; Goals; Impairment; Incidence; Individual; Ingestion; Intake; lean body mass; Maintenance; Marketing; Measures; meetings; Metabolic; Methodology; Methods; Muscle; muscle form; Muscle Proteins; Muscular Atrophy; Nitric Oxide; Nutrient; nutrition; Obesity; Outcome Study; Overweight; Phase; Production; Protein Biosynthesis; protein intake; Proteins; public health relevance; Randomized Clinical Trials; Relative (related person); Research Infrastructure; Resistance; response; sarcopenia; Site; Skeletal muscle structure; stable isotope; success; Taste Perception; technological innovation; Testing; Time; Tracer; Translational Research; volunteer; Whey Protein; Work

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----